CN1288750A - Hypoglycemic slimming medicine and its preparation - Google Patents
Hypoglycemic slimming medicine and its preparation Download PDFInfo
- Publication number
- CN1288750A CN1288750A CN 99119620 CN99119620A CN1288750A CN 1288750 A CN1288750 A CN 1288750A CN 99119620 CN99119620 CN 99119620 CN 99119620 A CN99119620 A CN 99119620A CN 1288750 A CN1288750 A CN 1288750A
- Authority
- CN
- China
- Prior art keywords
- medicine
- parts
- hypoglycemic
- herba
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 53
- 230000002218 hypoglycaemic effect Effects 0.000 title claims description 13
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 26
- 239000002775 capsule Substances 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 17
- 229920001661 Chitosan Polymers 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 6
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 239000002893 slag Substances 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 241001072382 Glechoma Species 0.000 claims description 2
- 241000219295 Portulaca Species 0.000 claims description 2
- 241000255791 Bombyx Species 0.000 claims 3
- 239000002552 dosage form Substances 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 52
- 102000004877 Insulin Human genes 0.000 abstract description 26
- 108090001061 Insulin Proteins 0.000 abstract description 26
- 229940125396 insulin Drugs 0.000 abstract description 25
- 210000004369 blood Anatomy 0.000 abstract description 19
- 239000008280 blood Substances 0.000 abstract description 19
- 230000035945 sensitivity Effects 0.000 abstract description 6
- 230000017531 blood circulation Effects 0.000 abstract description 5
- 210000004072 lung Anatomy 0.000 abstract description 5
- 210000000952 spleen Anatomy 0.000 abstract description 4
- 229920002101 Chitin Polymers 0.000 abstract description 3
- 210000003734 kidney Anatomy 0.000 abstract description 3
- 230000003248 secreting effect Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 241000255789 Bombyx mori Species 0.000 abstract description 2
- 230000006870 function Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 241000717671 Glechoma longituba Species 0.000 abstract 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 abstract 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 abstract 1
- 241001106041 Lycium Species 0.000 abstract 1
- 241000756042 Polygonatum Species 0.000 abstract 1
- 244000234609 Portulaca oleracea Species 0.000 abstract 1
- 235000001855 Portulaca oleracea Nutrition 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 235000021028 berry Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 19
- 206010012601 diabetes mellitus Diseases 0.000 description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 16
- 239000008103 glucose Substances 0.000 description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000037396 body weight Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 4
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 229940127017 oral antidiabetic Drugs 0.000 description 4
- 239000003538 oral antidiabetic agent Substances 0.000 description 4
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229960004580 glibenclamide Drugs 0.000 description 3
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 229940127003 anti-diabetic drug Drugs 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- GYSCAQFHASJXRS-FFCOJMSVSA-N beauvericin Chemical compound C([C@H]1C(=O)O[C@@H](C(N(C)[C@@H](CC=2C=CC=CC=2)C(=O)O[C@@H](C(=O)N(C)[C@@H](CC=2C=CC=CC=2)C(=O)O[C@@H](C(=O)N1C)C(C)C)C(C)C)=O)C(C)C)C1=CC=CC=C1 GYSCAQFHASJXRS-FFCOJMSVSA-N 0.000 description 2
- GYSCAQFHASJXRS-UHFFFAOYSA-N beauvericin Natural products CN1C(=O)C(C(C)C)OC(=O)C(CC=2C=CC=CC=2)N(C)C(=O)C(C(C)C)OC(=O)C(CC=2C=CC=CC=2)N(C)C(=O)C(C(C)C)OC(=O)C1CC1=CC=CC=C1 GYSCAQFHASJXRS-UHFFFAOYSA-N 0.000 description 2
- 108010079684 beauvericin Proteins 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 229960003243 phenformin Drugs 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010059245 Angiopathy Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002156 adsorbate Substances 0.000 description 1
- VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- -1 cyclic ester Chemical class 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- SOSNRENZYTXGAB-UHFFFAOYSA-N n-ethoxy-7h-purin-6-amine Chemical compound CCONC1=NC=NC2=C1NC=N2 SOSNRENZYTXGAB-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention discloses a medicine for reducing blood sugar and reducing weight. Said medicine comprises chitin, batryticated silkworm powder, rhubarb, polygonatum root, lycium berry, purslane, gynostemma pentaphyllum and glechoma longituba, which can be made into tablet and capsule, and possesses the functions of raising sensitivity and secretory volume of insulin, boosting qi, promoting blood circulation, moistening spleen and lung and enriching kidney yin. Said invention is unique in prescription and preparation method, and its therapeutic effect is obvious.
Description
The present invention relates to a kind of biologics in the medicine and hygiene fields and preparation method thereof, a kind of more specifically medicine for the treatment of diabetes and obesity and preparation method thereof.
Diabetes do not heal all the life, and extensively and serious, continue cardiovascular diseases and malignant tumor are for jeopardizing the third-largest disease of human life for complication.Chitosan
Diabetes are one group of syndromes, are to cause insulin deficit or generation insulin resistant in the body by different cause and onset of disease mechanism, and clinical is the general name of one group of heterogeneity metabolic disease of main performance unusually with sugar, protein and lipid metabolism.About the problem of diabetes etiology aspect, up to the present still fail to illustrate fully, cause not occurring as yet so far this sick specific drug of treatment.
The traditional Chinese medical science claims diabetes for quenching one's thirst, and thinks that its cause of disease is the plain body deficiency of YIN, eating and drinking without temperance, the sweet fertilizer of surfeit, multiple because of the imbalance of property will, labor is desired excessively, cause kidney yin deficient, lung, dryness of the stomach heat, with the passing of time disease prolongs, deficiency of YIN affecting YANG, deficiency of both YIN and YANG, the Chinese medicines of using in treatment more, suit the remedy to the case, advocate nourishing kidney-yin, QI invigorating void, change congestion, pure and impure letting out, the body resistance strengthening and constitution consolidating.
Doctor trained in Western medicine thinks that it is the result of pancreas degenerative that diabetes produce, and advocates with islets of langerhans class or oral antidiabetic drug.
Be used for the treatment of at present the medicine of diabetes both at home and abroad, have following thorny problem:
1. insulin is produced antibody with meeting for a long time, and biological activity reduces; Excessive serious hypoglycemia, the hypokalemia of causing of dosage can be because of the too fast cerebral edema that causes of extracellular osmotic pressure decline.The correct grasp of dosage is difficulty relatively, as urinary glucose determination, need stay twenty-four-hour urine liquid, and is cumbersome, and the not normal person of renal glucose threshold is not had reference value; As hold the measuring and calculating of abdomen blood glucose, cause patient's misery because of often drawing blood.
2. oral antidiabetic drug (Western medicine) mainly contains sulphur urine class and biguanides.About the influence of oral antidiabetic drug, show according to the U.S.'s clinical research observation of diabetes study group, no matter be phenformin (being insoral DBI) or tolbutamide (D through more than ten years to cardiovascular system
860), life-time service all makes the incidence rate of angiopathy or mortality rate improve, and simple diet control or insulinize group are high more than 2 times.Zoopery finds that also sulfonylurea drugs can act on cardiac muscle, increases the burden of heart, and biguanides easily brings out lactic acidosis.
3. Chinese patent medicine, effect is not fairly obvious, and the patient still has to depend on some Western medicine.Some Chinese patent medicine contains compositions such as glyburide as diabetes pill (10 diabetes pilles are equivalent to 1 glyburide) etc.Much so-called " folk prescription, secret recipe, specially good effect side " does powdered to some Chinese herbal medicine, adds glyburide or phenformin, encapsulated then, tablet forming or make electuary and sell.
4. decocting herb not quite is fit to allegro modern, not only use trouble, and it is long to act on the slow treatment phase.
Moreover, treat obesity at present and still do not have specific drug, thereby suppressed the curative effect of medicine greatly diabetes.The non-insulin-dependent diabetes mellitus patient who sees fat mostly more, the β cell hyperplasia of overweight people's excreting insulin, the effect of insulin is lowered in the prompting overweight people body, there is insulin resistant, for keeping blood glucose at normal level, insulin β cell is the hypertrophy hypertrophy then, increases the secretion of insulin amount.Long-term fat, insulin β cell will be impaired because of over load, and its result causes hypoinsulinism, brings out diabetes.We can say, only in the treatment diabetes, lose weight effectively, could treating both the principal and secondary aspects of a disease.
The objective of the invention is to be to provide a kind of hypoglycemic slimming medicine, its Chinese and Western combination, treating both the principal and secondary aspects of a disease has the sensitivity and the secretory volume that improve insulin, reduces insulin resistant, the effect of blood sugar lowering row fat, and the effect of tool benefiting QI for activating blood circulation, profit spleen lung, nourishing kidney-yin.The whole components of this medicine all are natural animals and plants extracts, have no side effect, and instant effect, easy to use.
The present invention also aims to provide a kind of preparation method of hypoglycemic slimming medicine.
Technical scheme of the present invention is:
Hypoglycemic slimming medicine is by following prescription, (consumption is a weight portion) of making by the special preparation method:
Chitosan 5-30 part BAIJIANG mycopowder 5-25 part Radix Et Rhizoma Rhei 1-5 part
Rhizoma Polygonati 1-5 part Fructus Lycii 1-10 part Herba Portulacae 2-20 part
Herb Gynostemmae Pentaphylli 2-20 part Herba Glechomae 1-15 part.
The optimum weight proportioning of medicine of the present invention is:
2 parts of 8 parts of Radix Et Rhizoma Rhei of 8 parts of BAIJIANG mycopowder of chitosan
5 parts of 2.5 portions of Herba Portulacaes of 2.5 parts of Fructus Lycii of Rhizoma Polygonati
3 parts of 5 parts of Herba Glechomaes of Herb Gynostemmae Pentaphylli.
BAIJIANG mycopowder wherein is that employing is a raw material because of muscardine infects lethal silkworm larva, extract its table quilt and epidermis, be dried and crushed into fine powder, it contains muscardine, chitin, ammonium oxalate, pyridine-2,6-dihydroxy acid, 6-N-ethoxy adenine, 2-linolenic acid, contains beauvericin (beauvericin), bassianins, the sterols composition of macromolecular cyclic ester peptide class in the muscardine; Chitosan is deacetylated the making of chitin in crustacean, insecticide and other invertebrates shell, is a kind of natural polycation polysaccharide, aboundresources, very easy on the market buying.
Above-mentioned each component is made medicine production method of the present invention is:
1. with Radix Et Rhizoma Rhei drying and crushing to 50 order fine powder, in the Porcelain Jar of packing into, add the ethanol that doubles weight, seal and soak after 10 days, press the slag extracting juice, discard residue, reclaim ethanol, the residue drying is made powder;
With Fructus Lycii and Rhizoma Polygonati after-18 ℃ of lyophilizations, processing powder is broken into 50 order fine powders, gets Herba Portulacae, Herb Gynostemmae Pentaphylli, Herba Glechomae again and is dried and crushed into 50 order fine powders, mix in the lump then and mix thoroughly, add 3 times, soak after 48 hours to the water of weight, extract medicine juice, spray drying is made powder;
3. get chitosan, BAIJIANG mycopowder and mix and mix thoroughly, be crushed to 120 order fine powders;
4. above-mentioned whole pulvis subtilis components are mixed by described this example and mix thoroughly, sterilization makes the powder of medicine of the present invention, but also tabletting or encapsulated.
Based on understanding and the Therapeutic Principle of Chinese and western medical science,, treatment mechanism of the present invention are described by following 5 with reference to the modern pharmacological research achievement to diabetes mechanism:
1. improve the sensitivity of insulin, reduce insulin resistant.Because it is acid that the diabetics that the deficiency of insulin causes, its body fluid are, if pH descends 0.1, the sensitivity of insulin descends 30%.Chitosan in this prescription can improve the sensitivity of insulin with pH regulator to alkalescence; The BAIJIANG mycopowder can stimulate the activity of insulin, reduces insulin resistant.
2. adjusting amount of insulin secretion.Chitosan in this prescription has the effect of endocrine regulation system, makes insulin secretion normal.This medical instrument has significant effect of weight reducing, and after patient's body weight dropped to ideal body weight, it is normal that insulin level can recover naturally.
3. blood sugar lowering fat-reducing.Contained amino and hydroxyl in the chitosan molecule has the good adsorption performance in this prescription, can adsorbate in unnecessary sugar and fat excrete; The Radix Et Rhizoma Rhei acid of Radix Et Rhizoma Rhei can stimulate big intestinal wall to cause that intestinal tube shrinks, and secretion increases, and makes big intestinal contents be easy to discharge; The BAIJIANG mycopowder can suppress the absorption of the intestines and stomach to glucose; The free fatty that total saponin of Gold Theragran can make fat tissue cell decompose and produce reduces about 28%, and the glucose that enters the synthetic neutral fat of cell reduces about 50%; The VB of Fructus Lycii
2, VB
6, VC, nicotinic acid etc. can participate in fat and change energy, reduce fat when health is released energy; The fatty acid of Herba Portulacae can suppress the generation of cholesterol and triglyceride.
4. benefiting QI for activating blood circulation, QI and blood is smooth along the drainage that helps unnecessary sugar and fat.Rhizoma Polygonati energy supplementing QI and nourishing YIN in this prescription; The BAIJIANG mycopowder has eliminating stagnation passes through, the respectful merit of falling of heat clearing away; The aloe-emodin of Radix Et Rhizoma Rhei can cause the hyperemia of pelvic cavity internal organs, and the effect of promoting blood circulation to restore menstrual flow is arranged; Herba Glechomae has the effect treating stranguria, heat-clearing and toxic substances removing of invigorating blood circulation.
5. moisten spleen lung, nourishing kidney-yin.Fructus Lycii tool nourishing the liver and kidney in this prescription is controlled the interior-heat effect of quenching one's thirst; Rhizoma Polygonati has the spleen reinforcing lung moistening, and QI invigorating is supported bright merit; The Saponin of Herb Gynostemmae Pentaphylli has identical nourishing function with the ginsenoside.
Clinical drug of the present invention uses the result to show that following advantage is arranged:
1. medicine of the present invention need not to add exogenous insulin, can improve the sensitivity and the secretory volume of endogenous insulin by regulating pH and hormonal system.
2. in conjunction with the Chinese and western medical science therapy, this medicine had both been had an effect that Chinese traditional treatment is quenched one's thirst, and the Western medicine (antidiabetic drug) of having again improves the effect of insulin level.
3. reduce serum total cholesterol, serum triglycerides and blood sugar content, improve the serum high-density LP cholesterol level, it is synthetic to suppress body fat, transforms subcutaneous accumulation fat, loses weight synchronously when blood sugar lowering.Alleviating of body weight reduced insulin β cell load, thereby can fundamentally nurse one's health the pancreas function of having degenerated, to reach the treating both the principal and secondary aspects of a disease curative effect.
4. to adopt the natural animal-plant extract be raw material in the present invention, good, nontoxic with the biological tissue affinity, has no side effect.
By following zoopery and clinical trial, can show the curative effect of medicine of the present invention.
1. zoopery.The method that adopts the intravenous injection approach to give alloxan (60mg/kg) is made the animal model of Kunming mouse diabetes.Inject and surveyed its cavity blood glucose value in back 72 hours, select the animal of blood glucose value more than 12mmol/L for use, study the influence of medicine of the present invention blood glucose.High sugared matched group and basic, normal, high three the dosage groups of medicine of the present invention are established in experiment, are respectively medicine 0.170mg/kg of the present invention, 0.340mg/kg and 0.680mg/kg body weight.Per os gives each dosage group mice medicine of the present invention 21 days, and high sugared matched group gives plain boiled water, surveys its sky serum blood glucose value.The result shows (seeing table 1 for details), and the blood glucose value of the basic, normal, high dosage group of medicine of the present invention significantly is lower than high sugared matched group 14.3% (p＜0.05), 18.8% (p＜0.01), 25.2% (p＜0.01) respectively.Illustrate that medicine of the present invention has significant hypoglycemic activity to the hyperglycemia mice due to the alloxan.Table 1 medicine of the present invention is to the influence of mice serum blood sugar content (x ± SD)
*: with the sugared matched group of high significant difference (p＜0.05) * * is arranged relatively: utmost point significant difference (p＜0.01) is relatively arranged with the sugared matched group of height
2. clinical trial: the present invention is through the clinical observation of 50 routine systems, and chooses and select the suitable diabetics of medical history, the state of an illness, age, sex and former Therapeutic Method 36 examples and be matched group.Select case from the endocrine special outpatient clinic, press the diabetes diagnosis standard that WHO formulated in 1985, the maturity-onset diabetes patient who makes a definite diagnosis, on the basis of dietetic therapy and medicine (oral antidiabetic drug and insulin) treatment, fasting glucose is 〉=7.8mmol/L person is the object of observation, wherein male 20 examples, women 30 examples, age 35-68 year.Course of disease half a year-30 year.Test group: on former treatment basis, stop using insulin, antidiabetic drug, lipid lowerers are obeyed medicine of the present invention.Matched group: blood sugar lowering, blood fat reducing treatment routinely.Before and after taking, same clothing, on same weighing machine, weigh in, adopt same procedure to make regular check on fasting glucose and blood fat, three months observation periods.Instructions of taking: 8/time (620mg/ grain).Day obeys 3 times, and ante cibum, boiled water took.Clinical effectiveness is as showing:
Table 2 is taken medicine of the present invention front and back blood glucose, blood fat mean concentration and body weight change
As can be seen from Table 2, body weight, fasting glucose concentration before two groups of tests, serum cholesterol and triglyceride concentration all do not have significant difference, but after test group is taken medicine of the present invention, body weight, blood glucose fall are all obviously greater than matched group, and serum cholesterol and serum triglycerides content also significantly are lower than matched group.Illustrate that medicine of the present invention has extremely significant hypoglycemic slimming effect to diabetes and obesity patient.
Clinical statistics shows: with medicament of the present invention 50 diabeticss are done therapeutic test, that obtains significant curative effect accounts for 72%, substantially effectively accounts for 24%, and invalid accounts for 4%, and total effective rate reaches 96%.
Embodiment:
Take by weighing spice by following proportioning:
Chitosan 40kg BAIJIANG mycopowder 40kg Radix Et Rhizoma Rhei 10kg
Rhizoma Polygonati 12.5kg Fructus Lycii 12.5kg Herba Portulacae 25kg
Herb Gynostemmae Pentaphylli 25kg Herba Glechomae 15kg
Production method is as follows:
1. with Radix Et Rhizoma Rhei drying and crushing to 50 order fine powder, in the Porcelain Jar of packing into, add 90% the ethanol that doubles weight, seal and soak after 10 days, press the slag extracting juice, discard residue, reclaim ethanol, the residue drying is made powder;
With Fructus Lycii and Rhizoma Polygonati after-18 ℃ of lyophilizations, processing powder is broken into 50 order fine powders, gets Herba Portulacae, Herb Gynostemmae Pentaphylli, Herba Glechomae again and is dried and crushed into 50 order fine powders, mix in the lump then and mix thoroughly, add 3 times to 60 ℃ of warm water of weight, soak and extract medicine juice after 48 hours, spray drying is made powder;
3. get chitosan, BAIJIANG mycopowder and mix and mix thoroughly, be crushed to 120 order fine powders;
4. above-mentioned whole pulvis subtilis components are mixed by described this example and mix thoroughly, sterilization makes the powder of medicine of the present invention, and is encapsulated.
Present embodiment to the index request of chitosan is: deacetylation 〉=95%, and viscosity 100-500mpas, moisture＜5%, ash＜05%, insoluble matter＜05%, pH value 7-7.5, health examination is qualified, and color and luster is white.
Claims (5)
1. hypoglycemic slimming medicine, its spy is that it is the medicament of being made by the following weight proportion raw material: chitosan 5-30 part Bombyx Batryticatus mycopowder 5-25 part Radix Et Rhizoma Rhei 1-5 part Rhizoma Polygonati 1-5 part Fructus Lycii 1-10 part Herba Portulacae 2-20 part Herb Gynostemmae Pentaphylli 2-20 part Herba Glechomae 1-15 part.
2. hypoglycemic slimming medicine according to claim 1 is characterized in that wherein the weight proportion of each raw material is: 3 parts of 5 parts of Herba Glechomaes of 5 parts of Herb Gynostemmae Pentaphylli of 2.5 portions of Herba Portulacaes of 2.5 parts of Fructus Lycii of 2 parts of Rhizoma Polygonatis of 8 parts of Radix Et Rhizoma Rhei of 8 parts of Bombyx Batryticatus mycopowder of chitosan.
3. according to claim 1 or the described hypoglycemic slimming medicine of claim 2, it is characterized in that said medicament is a said dosage form on any pharmaceutics.
4. hypoglycemic slimming medicine according to claim 3 is characterized in that said medicament is tablet or capsule.
5. a method for preparing above-mentioned hypoglycemic slimming medicine is characterized in that elder generation with Radix Et Rhizoma Rhei drying and crushing to 50 order fine powder, in the Porcelain Jar of packing into, adds the ethanol that doubles weight, seal and soak after 10 days, press the slag extracting juice, discard residue, reclaim ethanol, the residue drying is made powder; After-18 ℃ of lyophilizations, processing powder is broken into 50 order fine powders with Fructus Lycii and Rhizoma Polygonati, gets Herba Portulacae, Herb Gynostemmae Pentaphylli, Herba Glechomae again and is dried and crushed into 50 order fine powders, mix in the lump then and mix thoroughly, add 3 times to the water of weight, soak and extract medicine juice after 48 hours, spray drying is made powder; Get chitosan, Bombyx Batryticatus mycopowder and mix and mix thoroughly, be crushed to 120 order fine powders; Above-mentioned whole pulvis subtilis components are mixed by described this example mix thoroughly, sterilization makes drug powder of the present invention, but also tabletting or encapsulated.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 99119620 CN1288750A (en) | 1999-09-22 | 1999-09-22 | Hypoglycemic slimming medicine and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 99119620 CN1288750A (en) | 1999-09-22 | 1999-09-22 | Hypoglycemic slimming medicine and its preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1288750A true CN1288750A (en) | 2001-03-28 |
Family
ID=5280996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 99119620 Pending CN1288750A (en) | 1999-09-22 | 1999-09-22 | Hypoglycemic slimming medicine and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1288750A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1321648C (en) * | 2005-06-30 | 2007-06-20 | 华中科技大学同济医学院附属同济医院 | Plant-derived insulin sensitizer and preparation method and application thereof |
| CN103054920A (en) * | 2013-01-16 | 2013-04-24 | 济南康众医药科技开发有限公司 | Purslane for preventing and treating obesity |
| US12282179B2 (en) | 2021-04-27 | 2025-04-22 | Luxshare-Ict Co., Ltd | Image compensation device and prism carrying mechanism thereof |
-
1999
- 1999-09-22 CN CN 99119620 patent/CN1288750A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1321648C (en) * | 2005-06-30 | 2007-06-20 | 华中科技大学同济医学院附属同济医院 | Plant-derived insulin sensitizer and preparation method and application thereof |
| CN103054920A (en) * | 2013-01-16 | 2013-04-24 | 济南康众医药科技开发有限公司 | Purslane for preventing and treating obesity |
| US12282179B2 (en) | 2021-04-27 | 2025-04-22 | Luxshare-Ict Co., Ltd | Image compensation device and prism carrying mechanism thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
| CN106360310A (en) | Composition for dropping after meal blood sugar and application thereof | |
| CN102526478B (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| CN102526479A (en) | Health-care medicine formula with functions of enhancing immunity and lowering blood sugar | |
| CN1066332C (en) | Hypoglycemic compound capsule | |
| CN115779046B (en) | Traditional Chinese medicine composition, traditional Chinese medicine preparation and application for preventing and treating diabetes | |
| CN1288750A (en) | Hypoglycemic slimming medicine and its preparation | |
| CN105194301A (en) | Traditional Chinese medicine preparation for treating chronic cardiac failure | |
| CN105250989A (en) | Donkey-hide glue small peptide composition for resisting fatigue | |
| CN113499366B (en) | Composition with function of reducing blood sugar and blood fat simultaneously and preparation method thereof | |
| CN101491605A (en) | Combination with blood sugar reducing function and preparation method thereof | |
| CN104825821A (en) | Medicine for treating diabetes and preparation method thereof | |
| CN1947778A (en) | Hypoglycemic medicine preparation and its prepn. method | |
| CN114794478A (en) | Composition capable of reducing blood pressure, blood fat and blood sugar and application thereof | |
| CN102784230A (en) | Pharmaceutical composition preparation for treating nutritional anemia | |
| CN106177712A (en) | A kind of magnificent Bulbus Allii bean treating cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN104474103A (en) | Natural plant hypoglycemic agent and preparation method thereof | |
| CN103656196A (en) | Traditional Chinese medicine composition for treating cutaneous pruritus caused by diabetes and preparation method thereof | |
| CN1097333A (en) | A kind of pure plant health preparation glycolipid disappears and method for making | |
| CN103877533A (en) | Medicine composition containing melbine for treating diabetes and preparation method thereof | |
| CN101791350B (en) | Glibenclamide-containing traditional Chinese and western medicine composition | |
| CN101791351B (en) | Glipizide-containing traditional Chinese and western medicine composition | |
| CN1895504A (en) | Chinese medicine for treating osteoporosis and its preparation | |
| CN1196953A (en) | Chinese patent drug for treating chronic bronchitis and asthma | |
| CN101491584A (en) | Combination with blood sugar reducing function and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Li Xuhai Document name: Deemed as a notice of withdrawal |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |